BioSpace News Archive

Emerging preclinical and clinical literature support MSCs may be appropriate to develop for COVID-19 as well as non-COVID-19 ARDS ImStem’s investigational MSC candidate IMS001, for which FDA recently removed a clinical hold on an IND to begin a human study in multiple sclerosis, to be considered for further development in COVID19 and ARDS from other causes IMS001 is derived from AgeX human embryonic stem cell line ESI 053

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today published its 2019 Environmental, Social and Governance (ESG) Progress Report , demonstrating the company’s social impact and responsibility performance. The report includes 2020 goals for specific topics and clear alignment with the United Nations Sustainable Development Goals. For the first time, an external reviewer validated select report content. Th

Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company, today announced that it will host the Company’s 2020 Annual Meeting of Stockholders (“Annual Meeting”) virtually due to public health concerns resulting from the coronavirus (“COVID-19”) outbreak, and government-recommended and required limits on public gatherings. Holding the Annual Meeting online will also protect the health and safety of the Company’s stoc

TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that Michael S. Weiss, the Company’s Executive Chairman and Chief Executive Officer, will participate in a fireside chat during the Jefferies 2020 Healthcare Conference, being held virtually. The fireside chat is scheduled to take place on Wednesday, June 3, 2020 at 10:00 AM ET. A live webcast of this presentation will be available on the Events page, located within the Investors & Media sec

Adds Clinical Trial Site at University Hospital Basel and Appoints World Leading Psychedelics Researcher Dr. Matthias Liechti as Principal Investigator

CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announced that Dr. Wei-Wu He , Chairman & CEO will present an overview of the company and provide a business update at the Jefferies 2020 He

BioCryst Pharmaceuticals, Inc. announced that the compensation committee of BioCryst’s board of directors granted five newly-hired employees inducement options to purchase an aggregate of 147,500 shares of BioCryst common stock on May 29, 2020 as inducements material to each employee entering into employment with BioCryst.

Nephros, Inc. (Nasdaq: NEPH ), a commercial-stage company that develops and sells high performance water purification products and pathogen detection systems to the medical and commercial markets, today announced that it will be presenting at the upcoming Virtual Summer Summit on Tuesday, June 9 th at 10:55 AM ET. Andy Astor, COO & CFO of Nephros, will be giving the presentation and answering questions from i

Novocure (NASDAQ: NVCR) today announced the launch of MyLink, a new tool that allows patients to download their Optune usage data from the comfort of home without the need for an in-person visit by a Novocure Device Support Specialist. Novocure initiated a phased launch with an initial wave of 30 U.S. patients to be followed by a broad rollout to all U.S. patients in the coming months. Novocure prioritized and accelerate

LYON, France and NEWTON, Mass., June 02, 2020 (GLOBE NEWSWIRE) -- Alizé Pharma 3, a global company specialized in developing therapeutic peptides for rare endocrine and metabolic diseases, today announced it is rebranding as Amolyt Pharma. The new brand, which will be implemented immediately, comes ahead of the launch of the Company’s first clinical program. The new brand reflects the Company’s new ambitions and singular focus on building and advancing a portfolio of unique therapeutic pepti